Ticker: CHRS

Coherus Oncology, Inc. (NASDAQ: CHRS) has reported its financial results for the second quarter of 2025. The company continues to navigate the aftermath of significant strategic changes following the divestiture of its UDENYCA biosimilar business. Financial Performance Overview Here are the key a...

Coherus BioSciences, Inc. (NASDAQ: CHRS) recently reported its Q1 2025 financial results, showcasing both challenges and some encouraging developments. Key Highlights: Net Revenue: $7.6 million, up from $2.3 million in Q1 2024, primarily driven by increased sales of LOQTORZI. Net Loss: $56.6 mil...